Clover Health Investments, Corp. (CLOV)
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
Clover Health Is A 'Buy' Because Of Its AI
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health Investments: Real Turnaround, But Already Priced In
Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
Clover Health Is Proving Its Profit Model
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Eyes 2026 GAAP Profit as AI Platform Fuels Medicare Advantage Growth
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript
Clover Health Investments Q2 Earnings Call Highlights
Clover Health Investments NASDAQ: CLOV reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures.
Is Clover Health Finally Turning the Corner?
Clover Health (NASDAQ:CLOV) has spent years as a speculative bet on a technology-led Medicare Advantage model.
A Clover Health Director Sold Over 67,000 Company Shares. Here's a Closer Look at the Transaction.
Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.
